Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Mylan N.V. $6.5 Billion Notes Offering

Davis Polk advised the representatives of the initial purchasers on Rule 144A/Regulation S offerings by Mylan N.V. (“Mylan”) of $1.0 billion aggregate principal amount of its 2.500% senior…

Loxo Oncology, Inc. Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $41.4 million SEC-registered common stock offering of 1,926,250 shares of common stock of Loxo Oncology, Inc…

Anacor $5.2 billion acquisition by Pfizer

Davis Polk is advising Anacor Pharmaceuticals, Inc. on its approximately $5.2 billion acquisition by Pfizer Inc. The closing of the transaction, which is expected in the third quarter…

AbbVie Inc. Offering of $7.8 Billion Senior Notes

Davis Polk advised the representatives of the underwriters, in connection with an SEC-registered offering by AbbVie Inc. (“AbbVie”) of $7.8 billion aggregate principal amount of senior…

Aeglea BioTherapeutics, Inc. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million initial public offering by Aeglea BioTherapeutics, Inc. Aeglea’s…

Corvus Pharmaceuticals, Inc. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in the $70.5 million initial public offering by Corvus Pharmaceuticals, Inc. of 4,700,000…

Davis Polk Advises Hypermarcas on Debt Tender Offer

Davis Polk advised Hypermarcas S.A. in connection with its cash tender offer to purchase any and all of its outstanding $312.6 million 6.5% senior notes due 2021 and consent solicitation…
Back to top